SCHOTT PHARMA AG& CO KGAA (1SXP.DE) Stock Fundamental Analysis

FRA:1SXP • DE000A3ENQ51

14.78 EUR
-0.1 (-0.67%)
Last: Feb 27, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to 1SXP. 1SXP was compared to 18 industry peers in the Life Sciences Tools & Services industry. 1SXP has an excellent profitability rating, but there are some minor concerns on its financial health. 1SXP is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • 1SXP had positive earnings in the past year.
  • In the past year 1SXP had a positive cash flow from operations.
  • In the past 5 years 1SXP has always been profitable.
  • Each year in the past 5 years 1SXP had a positive operating cash flow.
1SXP.DE Yearly Net Income VS EBIT VS OCF VS FCF1SXP.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M

1.2 Ratios

  • The Return On Assets of 1SXP (9.26%) is better than 83.33% of its industry peers.
  • Looking at the Return On Equity, with a value of 16.21%, 1SXP belongs to the top of the industry, outperforming 88.89% of the companies in the same industry.
  • 1SXP has a Return On Invested Capital of 12.84%. This is amongst the best in the industry. 1SXP outperforms 88.89% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for 1SXP is above the industry average of 9.64%.
Industry RankSector Rank
ROA 9.26%
ROE 16.21%
ROIC 12.84%
ROA(3y)10.63%
ROA(5y)11.2%
ROE(3y)19.15%
ROE(5y)19.86%
ROIC(3y)14.59%
ROIC(5y)15.53%
1SXP.DE Yearly ROA, ROE, ROIC1SXP.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 2025 5 10 15 20

1.3 Margins

  • With a decent Profit Margin value of 15.13%, 1SXP is doing good in the industry, outperforming 77.78% of the companies in the same industry.
  • 1SXP's Profit Margin has improved in the last couple of years.
  • 1SXP has a better Operating Margin (19.08%) than 77.78% of its industry peers.
  • 1SXP's Operating Margin has improved in the last couple of years.
  • 1SXP has a worse Gross Margin (33.68%) than 61.11% of its industry peers.
  • 1SXP's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 19.08%
PM (TTM) 15.13%
GM 33.68%
OM growth 3Y-2.54%
OM growth 5Y4%
PM growth 3Y-0.93%
PM growth 5Y2.28%
GM growth 3Y-2.25%
GM growth 5Y0.1%
1SXP.DE Yearly Profit, Operating, Gross Margins1SXP.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 2025 10 20 30

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), 1SXP is creating some value.
  • 1SXP has about the same amout of shares outstanding than it did 1 year ago.
  • 1SXP has about the same amout of shares outstanding than it did 5 years ago.
  • 1SXP has a better debt/assets ratio than last year.
1SXP.DE Yearly Shares Outstanding1SXP.DE Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 50M 100M 150M
1SXP.DE Yearly Total Debt VS Total Assets1SXP.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

2.2 Solvency

  • 1SXP has a debt to FCF ratio of 7.05. This is a slightly negative value and a sign of low solvency as 1SXP would need 7.05 years to pay back of all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 7.05, 1SXP is in line with its industry, outperforming 50.00% of the companies in the same industry.
  • A Debt/Equity ratio of 0.08 indicates that 1SXP is not too dependend on debt financing.
  • 1SXP has a better Debt to Equity ratio (0.08) than 94.44% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF 7.05
Altman-Z N/A
ROIC/WACC1.43
WACC8.97%
1SXP.DE Yearly LT Debt VS Equity VS FCF1SXP.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.3 Liquidity

  • 1SXP has a Current Ratio of 1.58. This is a normal value and indicates that 1SXP is financially healthy and should not expect problems in meeting its short term obligations.
  • With a decent Current ratio value of 1.58, 1SXP is doing good in the industry, outperforming 61.11% of the companies in the same industry.
  • A Quick Ratio of 1.17 indicates that 1SXP should not have too much problems paying its short term obligations.
  • With a decent Quick ratio value of 1.17, 1SXP is doing good in the industry, outperforming 66.67% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.58
Quick Ratio 1.17
1SXP.DE Yearly Current Assets VS Current Liabilites1SXP.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • 1SXP shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -2.02%.
  • The Earnings Per Share has been growing by 13.78% on average over the past years. This is quite good.
  • Looking at the last year, 1SXP shows a small growth in Revenue. The Revenue has grown by 4.39% in the last year.
  • The Revenue has been growing by 11.04% on average over the past years. This is quite good.
EPS 1Y (TTM)-2.02%
EPS 3Y5.42%
EPS 5Y13.78%
EPS Q2Q%15.79%
Revenue 1Y (TTM)4.39%
Revenue growth 3Y6.3%
Revenue growth 5Y11.04%
Sales Q2Q%4.5%

3.2 Future

  • The Earnings Per Share is expected to grow by 7.31% on average over the next years.
  • The Revenue is expected to grow by 5.23% on average over the next years.
EPS Next Y2.98%
EPS Next 2Y8.11%
EPS Next 3Y9.33%
EPS Next 5Y7.31%
Revenue Next Year2.19%
Revenue Next 2Y4.57%
Revenue Next 3Y5.29%
Revenue Next 5Y5.23%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
1SXP.DE Yearly Revenue VS Estimates1SXP.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
1SXP.DE Yearly EPS VS Estimates1SXP.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 0.2 0.4 0.6 0.8 1

More info and screens

Find the best growth stocksShow best growing peers

5

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 15.24, the valuation of 1SXP can be described as correct.
  • 1SXP's Price/Earnings ratio is rather cheap when compared to the industry. 1SXP is cheaper than 83.33% of the companies in the same industry.
  • 1SXP is valuated rather cheaply when we compare the Price/Earnings ratio to 27.07, which is the current average of the S&P500 Index.
  • With a Price/Forward Earnings ratio of 13.04, 1SXP is valued correctly.
  • 1SXP's Price/Forward Earnings ratio is rather cheap when compared to the industry. 1SXP is cheaper than 88.89% of the companies in the same industry.
  • 1SXP's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 28.05.
Industry RankSector Rank
PE 15.24
Fwd PE 13.04
1SXP.DE Price Earnings VS Forward Price Earnings1SXP.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, 1SXP is valued a bit cheaper than the industry average as 77.78% of the companies are valued more expensively.
  • 66.67% of the companies in the same industry are cheaper than 1SXP, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 187.42
EV/EBITDA 8.33
1SXP.DE Per share data1SXP.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates 1SXP does not grow enough to justify the current Price/Earnings ratio.
  • The decent profitability rating of 1SXP may justify a higher PE ratio.
PEG (NY)5.11
PEG (5Y)1.11
EPS Next 2Y8.11%
EPS Next 3Y9.33%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. Dividend

5.1 Amount

  • 1SXP has a Yearly Dividend Yield of 1.21%. Purely for dividend investing, there may be better candidates out there.
  • In the last 3 months the price of 1SXP has falen by -22.70%. A price decline artificially increases the dividend yield. It may be a sign investors do not expect the dividend to last.
  • 1SXP's Dividend Yield is rather good when compared to the industry average which is at 0.44. 1SXP pays more dividend than 94.44% of the companies in the same industry.
  • 1SXP's Dividend Yield is slightly below the S&P500 average, which is at 1.82.
Industry RankSector Rank
Dividend Yield 1.21%

5.2 History

Dividend Growth(5Y)N/A
Div Incr Years1
Div Non Decr Years1
1SXP.DE Yearly Dividends per share1SXP.DE Yearly Dividends per shareYearly Dividends per share 2024 2025 2026 0.05 0.1 0.15

5.3 Sustainability

  • 1SXP pays out 15.99% of its income as dividend. This is a sustainable payout ratio.
DP15.99%
EPS Next 2Y8.11%
EPS Next 3Y9.33%
1SXP.DE Yearly Income VS Free CF VS Dividend1SXP.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2020 2021 2022 2023 2024 2025 50M 100M 150M
1SXP.DE Dividend Payout.1SXP.DE Dividend Payout, showing the Payout Ratio.1SXP.DE Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

SCHOTT PHARMA AG& CO KGAA

FRA:1SXP (2/27/2026, 7:00:00 PM)

14.78

-0.1 (-0.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-11
Earnings (Next)05-13
Inst Owners22.72%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap2.23B
Revenue(TTM)996.56M
Net Income(TTM)150.74M
Analysts75.79
Price Target19.93 (34.84%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.21%
Yearly Dividend0.16
Dividend Growth(5Y)N/A
DP15.99%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.32%
Min Revenue beat(2)-1.99%
Max Revenue beat(2)2.64%
Revenue beat(4)2
Avg Revenue beat(4)0.03%
Min Revenue beat(4)-2.27%
Max Revenue beat(4)2.64%
Revenue beat(8)3
Avg Revenue beat(8)0.09%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-6.13%
PT rev (3m)-32.63%
EPS NQ rev (1m)2.59%
EPS NQ rev (3m)-19.4%
EPS NY rev (1m)0%
EPS NY rev (3m)-14.62%
Revenue NQ rev (1m)0.48%
Revenue NQ rev (3m)-5.82%
Revenue NY rev (1m)-1.91%
Revenue NY rev (3m)-6.55%
Valuation
Industry RankSector Rank
PE 15.24
Fwd PE 13.04
P/S 2.23
P/FCF 187.42
P/OCF 14
P/B 2.39
P/tB 2.47
EV/EBITDA 8.33
EPS(TTM)0.97
EY6.56%
EPS(NY)1.13
Fwd EY7.67%
FCF(TTM)0.08
FCFY0.53%
OCF(TTM)1.06
OCFY7.14%
SpS6.62
BVpS6.18
TBVpS5.98
PEG (NY)5.11
PEG (5Y)1.11
Graham Number11.61
Profitability
Industry RankSector Rank
ROA 9.26%
ROE 16.21%
ROCE 16.05%
ROIC 12.84%
ROICexc 13.2%
ROICexgc 13.55%
OM 19.08%
PM (TTM) 15.13%
GM 33.68%
FCFM 1.19%
ROA(3y)10.63%
ROA(5y)11.2%
ROE(3y)19.15%
ROE(5y)19.86%
ROIC(3y)14.59%
ROIC(5y)15.53%
ROICexc(3y)15.01%
ROICexc(5y)16.12%
ROICexgc(3y)15.5%
ROICexgc(5y)16.82%
ROCE(3y)18.26%
ROCE(5y)19.44%
ROICexgc growth 3Y-6.05%
ROICexgc growth 5Y-8.67%
ROICexc growth 3Y-5.65%
ROICexc growth 5Y-7.55%
OM growth 3Y-2.54%
OM growth 5Y4%
PM growth 3Y-0.93%
PM growth 5Y2.28%
GM growth 3Y-2.25%
GM growth 5Y0.1%
F-Score7
Asset Turnover0.61
Health
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF 7.05
Debt/EBITDA 0.29
Cap/Depr 178.66%
Cap/Sales 14.76%
Interest Coverage 13.03
Cash Conversion 58.33%
Profit Quality 7.88%
Current Ratio 1.58
Quick Ratio 1.17
Altman-Z N/A
F-Score7
WACC8.97%
ROIC/WACC1.43
Cap/Depr(3y)260.7%
Cap/Depr(5y)265.72%
Cap/Sales(3y)16.46%
Cap/Sales(5y)16.64%
Profit Quality(3y)27.05%
Profit Quality(5y)27.58%
High Growth Momentum
Growth
EPS 1Y (TTM)-2.02%
EPS 3Y5.42%
EPS 5Y13.78%
EPS Q2Q%15.79%
EPS Next Y2.98%
EPS Next 2Y8.11%
EPS Next 3Y9.33%
EPS Next 5Y7.31%
Revenue 1Y (TTM)4.39%
Revenue growth 3Y6.3%
Revenue growth 5Y11.04%
Sales Q2Q%4.5%
Revenue Next Year2.19%
Revenue Next 2Y4.57%
Revenue Next 3Y5.29%
Revenue Next 5Y5.23%
EBIT growth 1Y18.83%
EBIT growth 3Y3.6%
EBIT growth 5Y15.48%
EBIT Next Year36.02%
EBIT Next 3Y18.01%
EBIT Next 5Y13.27%
FCF growth 1Y-55.75%
FCF growth 3Y6.15%
FCF growth 5Y12.98%
OCF growth 1Y-19.95%
OCF growth 3Y-0.4%
OCF growth 5Y11.5%

SCHOTT PHARMA AG& CO KGAA / 1SXP.DE FAQ

Can you provide the ChartMill fundamental rating for SCHOTT PHARMA AG& CO KGAA?

ChartMill assigns a fundamental rating of 5 / 10 to 1SXP.DE.


What is the valuation status for 1SXP stock?

ChartMill assigns a valuation rating of 5 / 10 to SCHOTT PHARMA AG& CO KGAA (1SXP.DE). This can be considered as Fairly Valued.


How profitable is SCHOTT PHARMA AG& CO KGAA (1SXP.DE) stock?

SCHOTT PHARMA AG& CO KGAA (1SXP.DE) has a profitability rating of 7 / 10.


Can you provide the financial health for 1SXP stock?

The financial health rating of SCHOTT PHARMA AG& CO KGAA (1SXP.DE) is 5 / 10.


What is the earnings growth outlook for SCHOTT PHARMA AG& CO KGAA?

The Earnings per Share (EPS) of SCHOTT PHARMA AG& CO KGAA (1SXP.DE) is expected to grow by 2.98% in the next year.